CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It is available with and without the Drug Affinity Complex (DAC) extension. It stimulates the pituitary to produce endogenous growth hormone.

CJC-1295 is a synthetic, long-acting analogue of Growth Hormone-Releasing Hormone (GHRH), designed as a tetrasubstituted 29-amino acid peptide. Its primary mechanism of action involves the stimulation of the pituitary gland to secrete endogenous Growth Hormone (GH). By binding to the GHRH receptor (GHRHR) on pituitary somatotrophs, it activates the G-protein coupled signaling cascade, primarily through the Gs protein-adenylyl cyclase-cAMP-protein kinase A pathway. This activation triggers the pulsatile release of GH into systemic circulation. Unlike native GHRH, which has a short half-life due to rapid degradation by dipeptidyl peptidase IV (DPP-IV), CJC-1295 incorporates Drug Affinity Complex (DAC) technology or specific amino acid substitutions that increase its stability and affinity for serum albumin.

This extension of the half-life allows for a sustained, physiological-like elevation of GH levels over several days, facilitating more consistent signaling. Upon the systemic release of GH, the peptide exerts its anabolic and anti-catabolic effects primarily through the induction of hepatic Insulin-like Growth Factor-1 (IGF-1) production. GH binds to the Growth Hormone Receptor (GHR) on hepatocytes, initiating the Janus kinase 2/signal transducer and activator of transcription 5 (JAK2/STAT5) signaling pathway, which upregulates the transcription of the IGF-1 gene.

Elevated circulating IGF-1 then acts in an autocrine, paracrine, and endocrine fashion to promote protein synthesis in skeletal muscle tissue. This occurs via the activation of the PI3K/Akt/mTOR signaling pathway, which facilitates ribosomal biogenesis and mRNA translation, thereby promoting muscle hypertrophy. Simultaneously, IGF-1 and GH act to prevent muscle catabolism by inhibiting the ubiquitin-proteasome pathway and reducing the expression of atrogin-1 and MuRF-1, which are key markers of muscle protein degradation. Beyond protein dynamics, CJC-1295 influences body composition through significant metabolic modulation in adipose and skeletal muscle tissues.

GH exerts a direct lipolytic effect by binding to receptors on adipocytes, stimulating hormone-sensitive lipase (HSL) and inhibiting lipoprotein lipase (LPL), which increases the mobilization of stored triglycerides into free fatty acids for oxidation. Simultaneously, the compound modulates substrate utilization, often shifting the body toward increased fat oxidation and glucose sparing. While GH can temporarily decrease insulin sensitivity, the subsequent rise in IGF-1 generally promotes glucose uptake in peripheral tissues. Furthermore, these pathways enhance collagen synthesis in connective tissues and stimulate osteoblast activity, contributing to structural integrity and bone density improvements.

Unlike exogenous androgens, CJC-1295 does not interact with the androgen receptor, nor is it a substrate for aromatase or 5-alpha reductase, ensuring its metabolic effects remain independent of sex-steroid signaling pathways.

CJC-1295 is not approved for human use by the FDA or other major regulators. It is not a controlled substance but is sold as a research chemical. Marketing for human consumption is not legal.

Products sold outside of regulated pharmaceutical channels are frequently subject to quality control failures, including incorrect peptide identity, underdosing, or contamination with bacterial endotoxins. Consumers should verify products via independent third-party laboratory testing using High-Performance Liquid Chromatography (HPLC) to confirm purity and mass spectrometry to verify the molecular weight and identity of the peptide.